Market open
Immatics/$IMTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Ticker
$IMTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
618
ISIN
NL0015285941
Website
Immatics Metrics
BasicAdvanced
$554M
-
-$0.22
0.87
-
Price and volume
Market cap
$554M
Beta
0.87
52-week high
$13.77
52-week low
$3.30
Average daily volume
605K
Financial strength
Current ratio
10.284
Quick ratio
9.868
Long term debt to equity
2.859
Total debt to equity
3.427
Interest coverage (TTM)
-64.31%
Management effectiveness
Return on assets (TTM)
-5.84%
Return on equity (TTM)
-4.78%
Valuation
Price to revenue (TTM)
3.15
Price to book
1.03
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-2.67
Growth
Revenue change (TTM)
93.57%
Earnings per share change (TTM)
-77.94%
3-year revenue growth (CAGR)
3.43%
3-year earnings per share growth (CAGR)
-5.28%
What the Analysts think about Immatics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Immatics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immatics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immatics News
AllArticlesVideos
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewsWire·2 days ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
GlobeNewsWire·3 weeks ago
Immatics N.V.: Trading Below Cash, But Not Without Reason
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immatics stock?
Immatics (IMTX) has a market cap of $554M as of May 15, 2025.
What is the P/E ratio for Immatics stock?
The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of May 15, 2025.
Does Immatics stock pay dividends?
No, Immatics (IMTX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Immatics dividend payment date?
Immatics (IMTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immatics?
Immatics (IMTX) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.